Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.55 |
| ▸ | TTK | P33981 | 10/20 | 0.48 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.46 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.46 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.46 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.46 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.46 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.46 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.46 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404865 | 0.84 | FLT3 (0.56) | FLT3TTKAURKB | |
| SCHEMBL5403440 | 0.84 | FLT3 (0.59) | FLT3TTKAURKB | |
| SCHEMBL5411370 | 0.83 | FLT3 (0.53) | FLT3TTKATP1A1ATP1B1ATP1A3 | |
| SCHEMBL5403916 | 0.81 | FLT3 (0.51) | FLT3TTK | |
| SCHEMBL5618954 | 0.81 | FLT3 (0.51) | FLT3TTK | |
| SCHEMBL5413864 | 0.81 | KDM4E (0.55) | FLT3TTKAURKAAURKB | |
| SCHEMBL14164627 | 0.80 | KDM4E (0.45) | TTKATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL5411416 | 0.80 | FLT3 (0.50) | FLT3TTKATP1A1ATP1B1ATP1A3 | |
| SCHEMBL5420238 | 0.80 | FLT3 (0.52) | FLT3TTK | |
| SCHEMBL5617891 | 0.80 | FLT3 (0.52) | FLT3TTKAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | claimed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | claimed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | FLT3 216/4885TTK 69/4885ATP1A1 1963/4885 |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | MAP3K8, MAP4K4, MAP3K2 | FLT3 215/4885TTK 369/4885ATP1A1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.